115 related articles for article (PubMed ID: 18612107)
1. Studies explore factors that underlie varied responses to cancer drugs.
Hampton T
JAMA; 2008 Jul; 300(2):155-6. PubMed ID: 18612107
[No Abstract] [Full Text] [Related]
2. Epoetin for cancer patients: a boon or a danger?
Brower V
J Natl Cancer Inst; 2003 Dec; 95(24):1820-1. PubMed ID: 14679148
[No Abstract] [Full Text] [Related]
3. [Concern about the safety of erythropoietin in cancer patients].
van der Lelie J
Ned Tijdschr Geneeskd; 2008 Apr; 152(16):920-2. PubMed ID: 18561786
[TBL] [Abstract][Full Text] [Related]
4. Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells.
Bennett CL; Lai SY; Sartor O; Georgantopoulos P; Hrushesky WJ; Henke M; Armitage JO
JAMA Oncol; 2016 Jan; 2(1):134-6. PubMed ID: 26606114
[No Abstract] [Full Text] [Related]
5. Pharmaceutical erythropoietin use in patients with cancer: is it time to abandon ship or just drop anchor?
Tefferi A
Mayo Clin Proc; 2007 Nov; 82(11):1316-8. PubMed ID: 17976350
[No Abstract] [Full Text] [Related]
6. Erythropoietin may impair, not improve, cancer survival.
Brower V
Nat Med; 2003 Dec; 9(12):1439. PubMed ID: 14647499
[No Abstract] [Full Text] [Related]
7. Erythropoietin to treat anaemia in patients with head and neck cancer.
Powles T; Shamash J; Liu W
Lancet; 2004 Jan; 363(9402):82. PubMed ID: 14724015
[No Abstract] [Full Text] [Related]
8. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
9. FDA finalizes REMS program for ESAs; Amgen continues to study risks.
Brower V
J Natl Cancer Inst; 2010 May; 102(9):592-3. PubMed ID: 20421565
[No Abstract] [Full Text] [Related]
10. ESAs further restricted, but debate continues.
Brower V
J Natl Cancer Inst; 2008 Oct; 100(19):1344-51. PubMed ID: 18812542
[No Abstract] [Full Text] [Related]
11. If only it were simple.
Winn RJ
J Natl Compr Canc Netw; 2005 Nov; 3(6):731. PubMed ID: 16316610
[No Abstract] [Full Text] [Related]
12. Erythropoietin: high profile, high scrutiny.
Crawford J
J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
[No Abstract] [Full Text] [Related]
13. [About the infrequent thrombotic events during erythropoietin therapy of anemia in ovarian cancer patients treated with chemotherapy].
Lehoczky O; Pulay T
Orv Hetil; 2007 Nov; 148(44):2081-5. PubMed ID: 17959551
[TBL] [Abstract][Full Text] [Related]
14. [Use of erythropoietin in the treatment of cancer-related anemia].
Huang JX; Meng FJ
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):877-8. PubMed ID: 22335959
[No Abstract] [Full Text] [Related]
15. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms.
Hadland BK; Longmore GD
J Clin Oncol; 2009 Sep; 27(25):4217-26. PubMed ID: 19636005
[TBL] [Abstract][Full Text] [Related]
16. [Anaemia and radiation therapy].
Denis F; Lartigau E
Cancer Radiother; 2004 Nov; 8 Suppl 1():S14-23. PubMed ID: 15679242
[TBL] [Abstract][Full Text] [Related]
17. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
Steensma DP
J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
[No Abstract] [Full Text] [Related]
18. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia.
Osterborg A; Aapro M; Cornes P; Haselbeck A; Hayward CR; Jelkmann W
Eur J Cancer; 2007 Feb; 43(3):510-9. PubMed ID: 17150352
[TBL] [Abstract][Full Text] [Related]
19. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
Hedley BD; Allan AL; Xenocostas A
Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin and cancer, a double-edged sword.
Ribatti D
Leuk Res; 2009 Jan; 33(1):1-4. PubMed ID: 18620752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
